Skip to Main Content

Favorite Table | Download (.pdf) | Print
ACT Adoptive T cell therapy
ACTH Adrenocorticotropic hormone
ADC Antibody-drug conjugate
AJCC American Joint Committee on Cancer
AKI Acute kidney injury
ALL Acute lymphoblastic leukaemia
ALT Alanine aminotransferase
AML Acute myeloid leukaemia
APC Antigen-presenting cell
APOBEC Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like
AST Aspartate aminotransferase
B-ALL B cell acute lymphoblastic leukaemia
BCG Bacillus Calmette-Guérin
BCMA B cell membrane antigen
B-NHL B cell non-Hodgkin lymphoma
BNP Brain natriuretic peptide
BRAF Serine/threonine-protein kinase B-Raf
CAR Chimeric antigen receptor
CD Cluster of differentiation
CEA Carcinoembryonic antigen
CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1
CIS Cytokine-inducible SH2-containing protein
CLL Chronic lymphocytic leukaemia
CM Cutaneous melanoma
CMR Cardiac magnetic resonance
CMV Cytomegalovirus
COP Cryptogenic organizing pneumonia
CRP C-reactive protein
CRS Cytokine release syndrome
CTCAE Common Terminology Criteria for Adverse Events
CTLA-4 Cytotoxic T lymphocyte-associated protein 4
DLBCL Diffuse large B cell lymphoma
ECOG Eastern Cooperative Oncology Group
EGF Epidermal growth factor
ER Oestrogen receptor
ERK Extracellular signal-regulated kinase
ESMO European Society for Medical Oncology
FDA Food and Drug Administration
FDG Fluorodeoxyglucose
FOXP3 Forkhead box P3
GCSF Granulocyte colony-stimulating factor
GITR Glucocorticoid-induced tumour necrosis factor receptor-related protein
GM-CSF Granulocyte macrophage colony-stimulating factor
gp Glycoprotein
HAVCR2 Hepatitis A virus cellular receptor 2
HD IL-2 High-dose interleukin-2
HER2 Human epidermal growth factor receptor 2
HLA Human leucocyte antigen
HMGB1 High mobility group box 1
HPV Human papilloma virus
HSV-1 Herpes simplex virus type 1
ICP Infected cell protein
ICPI Immune checkpoint inhibitor
IDO Indoleamine 2,3-dioxygenase
IFN Interferon
IL Interleukin
IL-13Rα2 Interleukin-13 receptor subunit α2
IL-6R Interleukin-6 receptor
irAE Immune-related adverse event
iRECIST Immune-based Response Evaluation Criteria in Solid Tumors
JAK-STAT Janus kinase-signal transducers and activators of transcription
LAG Lymphocyte-activation gene protein
LDH Lactate dehydrogenase
MAGE Melanoma-associated antigen
MAGE-A3 Melanoma-associated antigen 3
MAPK Mitogen-activated protein kinase
MART-1 Melanoma antigen recognized by T cells 1
MEK Mitogen-activated protein kinase kinase
MHC Major histocompatibility complex
MMM Mucosal malignant melanoma
MRCP Magnetic resonance cholangiopancreatography
MVAC Methotrexate, vinblastine, doxorubicin, cisplatin
NFAT Nuclear factor of activated T cells
NFκB Nuclear factor κB
NHL Non-Hodgkin lymphoma
NK Natural killer
NSCLC Non-small-cell lung carcinoma
OS Overall survival
OX40 Tumour necrosis factor receptor superfamily, member 4
PBMC Peripheral blood mononuclear cell
PD-1 Programmed cell death protein 1
PD-L1 Programmed death-ligand 1
PD-L2 Programmed death-ligand 2
PFS Progression-free survival
PFU Plaque-forming unit
PI3K Phosphoinositide 3-kinase
PJP Pneumocystis jirovecii pneumonia
PR Progesterone receptor
RCC Renal cell carcinoma
RCT Randomized controlled trial
RECIST Response Evaluation Criteria in Solid Tumors
RGMb Repulsive guidance molecule B
SCAD Segmental colitis associated with diverticulosis
scFv Single-chain variable fragment
SHP Src homology region 2-containing protein tyrosine phosphatase
SNP Single nucleotide polymorphism
TAA Tumour-associated antigen
TCR T cell receptor
TGF Transforming growth factor
TIGIT T cell immunoreceptor with immunoglobulin and ITIM domains
TIL Tumour-infiltrating lymphocyte
TIM T cell immunoglobulin and mucin domain
TKI Tyrosine kinase inhibitor
TNF Tumour necrosis factor
TSA Tumour-specific antigen
T-VEC Talimogene laherparepvec
ULN Upper limit of normal
VEGF Vascular endothelial growth factor

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.